% | $
Quotes you view appear here for quick access.

Boston Scientific Corporation Message Board

  • minharry minharry Jul 28, 1998 5:44 PM Flag

    BSX shy of 1cent, see you tomorrow at 60

    Exchange rate is worse than ever, ravernue grow
    at 7%, earning
    is shy of expection, spent a
    stupid amount to acqure Snyder,
    ------all these facts
    will send the stock down to 60 and under.

    only positive about BSX is its will-be-approved stent.
    Otherwise, BSX is worth only $40/share as

    Stop sell BSX tomorrow if it drops 2 or more points.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • You sure look like an idiot don't you. You are a
      prime example of "why you shouldn't read message boards
      for investment advice" I wish Bsx did go down a few
      points on Wed. morning (and rebound)so you would have
      sold your shares. Remember the NIR is only one small
      piece of the pie that BSX offers.

    • Reads like cries of desperation. You can jump ship anytime.I second grabsnort, long term (confident) holder, not nervous trader.Reliable model 9000

      • 2 Replies to HIABLM
      • The company missed earnings by one penny per
        share. Two things contributed to this Asian Markets and
        the delayed appoval. If these two items were on track
        the comapny would have blown wall street away. I am
        confident that the NIR will cause a blip that the traders
        were waiting for, but the company fundamentals will
        keep the equity high(er) for the long range shooters!

      • Just a thought. Only missed earnings by .01
        without NIR stent. Had stent been approved as originally
        thought in June, would have blown numbers out of water.
        Sales are solid, remember Scimed is getting hurt w/o
        the stent, affecting bundling of other products. The
        Schneider deal was expensive, but the intellectual property
        that was purchased will pay back huge dividends long
        term. Schneider was not purchased for just sales!
        stock dips, that is buying opportunity. Nir is key to
        Wall Street, performance will be graded more severely
        once stent is released. If NIR is a bust, then there
        is problems long term. Strret will react favorable
        to this earning s report. Shorters be careful,
        especially with the Nir approval around the corner.

22.44+0.56(+2.50%)Oct 25 4:01 PMEDT